Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - Upstream Bio ( NASDAQ:UPB )
- Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes -
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
- Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites ...
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds - Upstream Bio ( NASDAQ:UPB )
Verekitug met all primary and key secondary endpoints, reducing nasal polyp and congestion scores over 24 weeks. No serious adverse events were reported, supporting a strong safety profile consistent with earlier studies. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day ...
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP )
Positive top-line results for VIBRANT Phase 2 clinical trial of verekitug in CRSwNP with once every 12 week dosing ...
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP )
Upstream Bio to Host Conference Call/Webcast to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Patients with ...
Upstream Bio ( UPB ) Q2 R&D Soars 169%
Upstream Bio ( NASDAQ:UPB ) , a biotechnology company developing new therapies for respiratory diseases, released its second quarter 2025 results on August 6, 2025. The main headline was rapid advancement in clinical trials for its lead drug candidate, verekitug, with major enrollment milestones ...
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday - Alerus Financial ( NASDAQ:ALRS ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Monday. Shares of Alerus Financial Corporation ALRS rose sharply during Monday's session following better-than-expected quarterly results.
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease ( COPD )
- Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor ...
Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology ( EAACI ) Congress 2025
Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at ...
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Upstream Bio ( NASDAQ:UPB )
WALTHAM, Mass., June 04, 2025 ( GLOBE NEWSWIRE ) -- Upstream Bio, Inc.
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Upstream Bio to Present at the Goldman Sachs 46th Annual Global Healthcare Conference ...
Upstream Bio Appoints Stacy Price as Chief Technology Officer - Upstream Bio ( NASDAQ:UPB )
WALTHAM, Mass., May 20, 2025 ( GLOBE NEWSWIRE ) -- Upstream Bio, Inc. UPB, a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer.
Upstream Bio Appoints Stacy Price as Chief Technology Officer
WALTHAM, Mass., May 20, 2025 ( GLOBE NEWSWIRE ) -- Upstream Bio, Inc. ( Nasdaq: UPB ) , a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology ...
Amtech Systems, Tesla And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Amtech Systems ( NASDAQ:ASYS ) , Antelope Ent Hldgs ( NASDAQ:AEHL )
U.S. stock futures were lower this morning, with the Dow futures falling around 1% on Thursday. Shares of Amtech Systems Inc ASYS fell sharply in today's pre-market trading after the company cut its revenue forecast for the second quarter.
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket - Amtech Systems ( NASDAQ:ASYS ) , Antelope Ent Hldgs ( NASDAQ:AEHL )
Shares of ReShape Lifesciences Inc. RSLS rose sharply in today's pre-market trading after the company announced a partnership with Motion Informatics to exclusively import and distribute neuromuscular rehabilitation devices in the US. ReShape Lifesciences shares jumped 82.2% to $0.6232 in ...
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps. top-line data expected in the second half of ...
Upstream Bio Can Beat AstraZeneca Asthma Drug: Analyst - Upstream Bio ( NASDAQ:UPB )
Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering ( IPO ) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Eaton Corp ( NYSE:ETN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays analyst George Wang initiated coverage on Celestica Inc.
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Upstream closes $293 million upsized IPO including full exercise of underwriters' option to purchase additional shares ...
